Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs

Richard Ahn 1*, Rashmi Gupta 1, Kevin Lai 1, Nitin Chopra 1,2, Sarah T. Arron 1 and Wilson Liao 1

Abstract

Background: Psoriasis is an immune-mediated, inflammatory disorder of the skin characterized by chronic inflammation and hyperproliferation of the epidermis. Differential expression analysis of microarray or RNA-seq data have shown that thousands of coding and non-coding genes are differentially expressed between psoriatic and healthy control skin. However, differential expression analysis may fail to detect perturbations in gene coexpression networks. Sensitive detection of such networks may provide additional insight into important disease-associated pathways. In this study, we applied weighted gene coexpression network analysis (WGCNA) on RNA-seq data from psoriasis patients and healthy controls.

Results: RNA-seq was performed on skin samples from 18 psoriasis patients (pre-treatment and post-treatment with the TNF-α inhibitor adalimumab) and 16 healthy controls, generating an average of 52.3 million 100-bp paired-end reads per sample. Using WGCNA, we identified 3 network modules that were significantly correlated with psoriasis and 6 network modules significantly correlated with biologic treatment, with only 16% of the psoriasis-associated and 5% of the treatment-associated coexpressed genes being identified by differential expression analysis. In a majority of these correlated modules, more than 50% of coexpressed genes were long non-coding RNAs (lncRNA). Enrichment analysis of these correlated modules revealed that short-chain fatty acid metabolism and olfactory signaling are amongst the top pathways enriched for in modules associated with psoriasis, while regulation of leukocyte mediated cytotoxicity and regulation of cell killing are amongst the top pathways enriched for in modules associated with biologic treatment. A putative autoantigen, LL37, was coexpressed in the module most correlated with psoriasis.

Conclusions: This study has identified several networks of coding and non-coding genes associated with psoriasis and biologic drug treatment, including networks enriched for short-chain fatty acid metabolism and olfactory receptor activity, pathways that were not previously identified through differential expression analysis and may be dysregulated in psoriatic skin. As these networks are comprised mostly of non-coding genes, it is likely that non-coding genes play critical roles in the regulation of pathways involved in the pathogenesis of psoriasis.

Keywords: Psoriasis, Gene expression, RNA-seq, Long non-coding RNA (lncRNA), Weighted gene coexpression network analysis (WGCNA)
Background
Psoriasis is an immune-mediated, inflammatory disorder of the skin, characterized by chronic inflammation and subsequent hyperproliferation of the epidermis that results in silvery scales and a thickening of the skin. In the past decade, microarray-based differential expression studies have shown that hundreds of genes that are differentially expressed between psoriatic and healthy control skin [1–4]. More recently, RNA-seq-based differential expression studies, including a study by Li et al. [5], have dramatically increased the number of differentially expressed genes (DEGs) found between psoriatic and healthy skin, with the number of known DEGs in the thousands.

However, while differential expression analyses have successfully revealed transcriptomic signatures comprised of many individual DEGs, differential expression analysis may fail to detect important biological pathways or gene-gene interactions associated with disease due to a focus on the effect of individual genes rather than on the effect of networks of genes. Gene coexpression network analysis methods were developed to understand the relationship between pairs of genes and ultimately, gene networks or modules that are associated with a distinct biological function. Unweighted gene coexpression methods constructed these networks using pairwise correlations [6], Bayesian graphical models [7], or linear regression [8]. Weighted gene coexpression network analysis (WGCNA) [9] builds upon these previous unweighted methods by implementing a correlation-based soft-thresholding weight that prioritizes the strongest pairwise correlations and penalizes weaker ones and complements differential expression analysis by testing for association between a disease and networks of correlated genes. Unlike methods such as Gene Set Enrichment Analysis [10], the WGCNA framework is based on the rationale that gene networks can be constructed with gene correlation matrices alone, without prior network or pathway information that can introduce bias. Furthermore, WGCNA offers a way to prioritize the most important genes in a given network by calculating a measure of connectivity for each gene which is based on the number of correlations between each gene and all other genes in the network. A WGCNA-based screen reached a higher validation rate than a differential expression analysis based approach in identifying a biomarker for glioblastoma [11]. WGCNA has also been successfully applied in screening for disease-associated pathways, molecular targets, and candidate genes in chronic fatigue syndrome [12], Sjögren’s Syndrome [13], coronary heart disease [14], and inflammatory bowel disease [15].

Although WGCNA has been used to identify networks of coding genes associated with psoriasis [5, 16], WGCNA has not been used to identify networks of coding genes and long non-coding RNAs (lncRNAs). Therefore, we applied WGCNA to coding genes and lncRNAs sequenced by RNA-seq on lesional skin samples from psoriasis patients before (PP) and after treatment (PT) with a TNF-α inhibitor, adalimumab, and on healthy control skin (NN). Here we report the identification of novel networks of coding genes and lncRNAs associated with psoriasis and response to therapy and show that WGCNA uncovers additional biological pathways compared to differential expression analysis alone.

Methods
RNA-seq and differential expression of coding genes and lncRNAs in lesional psoriatic skin tissue
18 adult subjects with chronic plaque psoriasis were recruited from the University of California San Francisco (UCSF) Dermatology Department. A board certified dermatologist confirmed the diagnosis of psoriasis. The participants were required to have affected body surface area > 10 % and to not already be on systemic medications for their psoriasis. Among the 18 subjects, 4 were female, the mean age was 39.2 years (s.d. = 9.7 years), and the mean body mass index was 28.9 (s.d. = 6.2). Five millimeter punch biopsies were taken from the edge of a psoriatic plaque of each patient. Two skin biopsies were taken from each participant, the first prior to the initiation of adalimumab and the second one month after starting treatment. The mean Psoriasis Area and Severity Index (PASI) score prior to treatment was 14.6 (s.d. = 3.6) and after one month of adalimumab treatment was 7.0 (s.d. = 3.9), with a mean improvement of the PASI of 53.1 %. Sixteen normal skin samples were obtained from healthy control surgical discard specimens.

We prepared cDNA libraries from ribosome-depleted RNA extracted from skin biopsies of 18 psoriatic patients and 16 healthy controls that were sequenced on the Illumina HiSeq 2000 platform, which yielded an average of 52.3 million 100-bp paired-end reads per sample. Sequenced reads were aligned to the hg19/GRCh37 human reference genome using TopHat2 [17]. Gene annotations for 23 K coding genes and 67 K lncRNAs (including lincRNAs) were obtained from RefSeq [18] and Hangauer et al.’s dataset S3 [19], respectively. We used CuffDiff [20] to test for differential expression.

Weighted gene coexpression network analysis
After expression values were normalized to the number of reads per kilobase per million reads, QC was performed on the matrix of normalized expression values to remove any transcripts with either zero variance or a missing value and remove samples that were outliers in an initial unsupervised hierarchical clustering analysis.
(9303 genes, 3 control samples). After QC, a weighted adjacency matrix was created, defined as, $A_{ij} = (|\text{cor}(x_i, x_j)|)^{\beta}$, where $x_i$ and $x_j$ are the $i$-th and $j$-th genes, respectively. The soft thresholding power parameter, $\beta$, was set to 6 after a sensitivity analysis of scale-free topology was performed. This weighted adjacency matrix was used to generate a topological overlap matrix (TOM) and dendrogram. A dynamic hybrid branch cutting method was implemented on the resulting TOM-based dendrogram to identify module eigengenes (ME). MEs are the principal components for each gene expression module after a singular value decomposition is performed on the TOM. A cut height of 0.2 was set to merge MEs that have a correlation of 0.8 or greater. A phenotypic trait-based gene significance measure was defined as $G_{si} = -\log_{10}(p_{\text{cor}(x_i, t)})$, where $x_i$ is the $i$-th gene and $t$ is the binary indicator variable for psoriasis case status (or treatment status). An ME significance was defined as $\text{MSE}_j = |\text{cor}(x_{ji}, t)|$, where $x_{ji}$ is the $j$-th gene and $t$ is the binary indicator. Module membership, MM, for the $i$-th gene was defined as, $\text{MM} = |\text{cor}(x_{i}, ME)|$.

'Unless otherwise specified, ‘cor’ refers to Pearson correlation.

Pathway analysis
We uploaded lists of DEGs and lists of genes from the significantly correlated modules between NN and PP and between PP and PT to the Illumina NextBio Research platform for GO term enrichments and Broad MSigDB Canonical Pathways enrichment. DAVID (https://david.ncifcrf.gov) was used to find KEGG pathway enrichments.

Results
Network analysis of coding genes and IncRNAs in healthy and psoriatic skin
We analyzed RNA-seq data from 18 psoriatic patients and 16 healthy controls previously described in Gupta et al. [21]. Traditional differential expression analysis in PPvNN revealed that 5328 genes were differentially expressed (FDR ≤ 0.05), including 4357 coding genes and 971 IncRNAs (Additional file 1). In PPvPT, 2657 genes were differentially expressed (FDR ≤ 0.05), including 2500 coding genes and 157 IncRNAs (Additional file 1). A validation of the DE IncRNAs was performed by implementing reverse transcriptase qPCR on IncRNAs from 17 cases and 14 healthy controls. Four DE IncRNAs (TRHDE-AS1, CYP4Z2P, HINT1, and RPSAP58) were chosen for validation, with three of the four IncRNAs (TRHDE-AS1, CYP4Z2P, and HINT1) being DE in the same direction as found in the RNA-seq analysis. A detailed description of differential expression analysis of IncRNAs and validation of DE IncRNAs by qPCR is provided in Gupta et al. [21]. The top 3 GO terms from PPvNN were viral reproductive process ($p = 1.40e-98$), nuclear division ($p = 1.30e-87$), and mitosis ($p = 1.30e-87$), all with significantly up-regulated genes. From PPvPT, the top 3 GO terms were mitosis ($p = 5.60e-100$), nuclear division ($p = 5.60e-100$), and viral reproductive process ($p = 6.80e-93$), all with significantly down-regulated genes. The full list of GO terms are in Additional file 2.

To determine if a network analysis approach reveals psoriasis-associated biological pathways that were not previously found by differential expression analysis, we started by asking which coding and non-coding genes are uniquely identified by network analysis versus differential expression analysis. To answer this question, we implemented WGCNA to identify module eigengenes (MEs) that correlated with either psoriasis or with positive response to biologic treatment. MEs are the ideal unit to correlate with external traits because they are the first principal component of a network of coexpressed genes and thus account for the most variance in the data. We generated 64 MEs in PPvNN, 3 of which were significantly correlated with psoriasis (7849 genes; FDR ≤ 0.05) (Table 1). In PPvPT, we generated 70 MEs, 6 of which were significantly correlated with positive response to biologic treatment (5775 genes; FDR ≤ 0.05) (Table 2).

Although there was some overlap between genes identified by DE and WGCNA, the WGCNA approach identified a large number of genes significantly correlated with psoriasis and biologic treatment that were not identified by differential expression analysis (Fig. 1). We found that 84 % and 95 % of genes identified by WGCNA as being associated with psoriasis (PPvNN) or psoriasis treatment (PPvPT), respectively, were not identified by DE analysis. In PPvNN, 93 coding genes that were exclusively identified via DE were amongst the top 100 over-expressed coding genes in PP while 22 coding genes identified via DE only were amongst the top 100 under-expressed

| Table 1 | Top module eigengenes that are significantly correlated with psoriasis (FDR ≤ 0.05) between PP and NN |
|---------|---------------------------------|
| Module  | Trait Correlation | FDR Trait Correlation | # of genes | # of IncRNA | % IncRNA | # DE RefSeq | # DE IncRNAs |
| blue    | −0.86              | 2.42E-08              | 5719      | 2655       | 46 %     | 1031       | 236         |
| salmon  | 0.81               | 1.39E-06              | 2002      | 1820       | 91 %     | 3          | 0           |
| lavenderblush3 | 0.74              | 3.36E-05              | 128       | 113        | 88 %     | 0          | 0           |
coding genes in PP. 87 lncRNAs identified via DE only were amongst the top 100 over-expressed lncRNAs while 52 such lncRNAs were amongst the top 100 under-expressed lncRNAs. The 93 over-expressed coding genes were significantly enriched for GO terms such as keratinization \((p = 3.69e-20)\), keratinocyte differentiation \((p = 1.82e-15)\), and cytokine-mediated signaling pathway \((p = 1.18e-8)\), replicating results from previous studies.

For PPvPT, 73 coding genes identified via DE only were amongst the top 100 over-expressed coding genes in PT, while 99 coding genes were amongst the top 100 under-expressed coding genes in PT. Of the 157 DE lncRNAs in PPvPT, 150 were exclusively identified by DE analysis, with 9 lncRNAs under-expressed and 141 lncRNAs over-expressed in PP. Unsurprisingly, the 99 under-expressed coding genes were significantly enriched for keratinization \((p = 4.43e-9)\), keratinocyte differentiation \((p = 1.41e-7)\), and inflammatory response \((p = 2.82e-7)\), which coincides with the efficacy of the treatment with adalimumab.

We next examined the two most significantly correlated modules from both PPvNN and PPvPT. For PPvNN, the module most significantly correlated with psoriasis was the blue module \((\rho = -0.86, p = 3.77e-10)\). The negative correlation indicates that the genes in this module were underexpressed in PP. The top 3 GO terms that were significantly enriched for in the blue module included “lipid biosynthetic process” \((p = 2.50e-61)\), “fatty acid metabolic process” \((p = 4.10e-57)\), and “mitochondrial matrix” \((p = 3.90e-53)\) (Table 3; Additional file 3).

In contrast to the blue module, 90 % of the 2002 genes in the salmon module were lncRNAs and of the 182 coding genes, only 3 were DEGs, with none
of the lncRNAs being DEGs. With the exception of "innate immune response", none of the top salmon module GO terms were amongst the top 20 terms enriched for in the DE genes.

For PPvPT, the module most correlated with treatment response was the sienna3 module ($\rho = 0.71$, $p = 1.18e-6$). The top 3 GO terms that were enriched for are "regulation of leukocyte mediated cytotoxicity" ($p = 1.40e-5$), "regulation of cell killing" ($p = 1.90e-5$), and "leukocyte activation" ($p = 1.0e-4$) (Table 4; Additional file 4). A majority of the 564 genes (83%) in the sienna3 module were lncRNAs. Almost none of the genes were differentially expressed, with just one coding DEG.

The next most correlated module for treatment response in PPvPT was the lightyellow module ($\rho = 0.66$, $p = 1.22e-5$). GO terms that the lightyellow module was enriched for included "protein complex disassembly" ($p = 1.0e-10$), "protein targeting to ER" ($p = 1.1e-10$), and "establishment of protein localization to endoplasmic reticulum" ($p = 1.1e-10$) (Table 4; Additional file 4). Again the majority of the genes in this module were lncRNAs (82%) and only one gene (coding) was a DEG. Interestingly, while nearly all of the overlapping DEGs from PPvNN (Fig. 1a) are found in the blue module, most of the 304 overlapping genes (Fig. 1b) from PPvPT are not found in the top three PPvPT modules. None of the top GO terms enriched for in either of the PPvPT sienna3 or lightyellow modules, were amongst the top 20 GO terms enriched for in the DE genes.

Next, we performed intramodular analysis to determine "hub genes" or genes that were the most connected to other genes and individually significant genes. Figure 2a graphically illustrates the process from identification of the most significant MEs to intramodular analysis. We defined a hub gene as a gene with gene significance (GS) $\geq 10$ and module membership (MM) $\geq 0.8$. We performed intramodular analysis on the top 3 modules in both PPvNN and PPvPT. Within the blue module of PPvNN, we identified 33 hub genes (Fig. 2b; Additional files 5), including HOXA9, HOXA10, and GGH. 28 of the 33 hub genes were lncRNAs and all but one of the hub genes (MARCH6) was differentially expressed in PPvNN. Genes in the other modules (for

| Module | GO Term                                           | $p$   | Broad MSigDB Canonical Pathway                              | $p$   |
|--------|---------------------------------------------------|-------|------------------------------------------------------------|-------|
| Blue   | lipid biosynthetic process                        | 2.50E-61 | Genes involved in Metabolism of lipids and lipoproteins | 6.10E-71 |
|        | fatty acid metabolic process                      | 4.10E-57 | Peroxisome                                                | 5.30E-39 |
|        | mitochondrial matrix                              | 3.90E-53 | Valine, leucine and isoleucine degradation                | 5.60E-35 |
|        | mitochondrial membrane                            | 3.00E-52 | Genes involved in Generic Transcription Pathway          | 6.90E-34 |
|        | mitochondrial inner membrane                      | 2.20E-51 | Genes involved in Fatty acid, triacylglycerol, and ketone body metabolism | 5.90E-32 |
|        | organic acid catabolic process                    | 1.70E-48 | Genes involved in Cholesterol biosynthesis            | 2.90E-26 |
|        | peroxisome                                       | 5.30E-42 | Genes involved in The citric acid (TCA) cycle and respiratory electron transport | 6.40E-23 |
|        | microbody                                        | 5.30E-42 | Fatty acid metabolism                                      | 1.20E-20 |
|        | cofactor binding                                 | 5.40E-40 | Propanoate metabolism                                      | 2.40E-20 |
|        | steroid metabolic process                         | 3.00E-36 | Genes involved in Phospholipid metabolism                | 2.60E-18 |
| Salmon | immune effector process                           | 0.0001 | Olfactory transduction                                      | 3.20E-16 |
|        | innate immune response                            | 0.0002 | Genes involved in Olfactory Signaling Pathway            | 2.70E-12 |
|        | cell surface                                      | 0.0002 | Genes involved in Hyaluronan uptake and degradation       | 5.90E-05 |
|        | lymphocyte mediated immunity                      | 0.0002 | Genes involved in Hyaluronan metabolism                   | 0.0001 |
|        | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 0.0003 | Genes involved in Glycosaminoglycan metabolism | 0.0003 |
|        | adaptive immune response                          | 0.0004 | Sulfur metabolism                                         | 0.0006 |
|        | leukocyte mediated immunity                       | 0.0004 | Genes involved in Chondroitin sulfate biosynthesis        | 0.0009 |
|        | ion channel activity                              | 0.0005 | Glycosaminoglycan biosynthesis - chondroitin sulfate     | 0.001 |
|        | positive regulation of immune response            | 0.0005 | PAR1-mediated thrombin signaling events                  | 0.001 |
|        | response to bacterium                             | 0.0006 | Genes involved in Developmental Biology                 | 0.0013 |

Table 3: Top 10 GO Term and Broad MSigDB Canonical Pathway enrichments for 2 most correlated modules in PPvNN

Ahn et al. BMC Genomics (2016) 17:841 Page 5 of 10
both PPvNN and PPvPT) did not meet GS or MM thresholds defined above (Additional files 6).

**Discussion**

Differential expression analysis can identify individual genes that are differentially expressed between cases and controls. In this study, we investigated whether WGCNA would uncover biological pathways associated with psoriasis and treatment with a biologic drug that are not identified by differential expression analysis. Our results show that most of the genes identified in psoriasis or treatment-associated co-expression networks are not differentially expressed. We also inferred the function of non-coding genes that were coexpressed with coding genes in networks of genes correlated with psoriasis or treatment response by testing these coexpression networks for GO or KEGG term enrichment.

**Dominance of IncRNAs in network modules**

We were surprised to discover that most of the genes in the majority of the modules that were significantly correlated with psoriasis were IncRNAs, particularly in PPvNN, where 2 of the 3 significantly psoriasis-correlated modules were at least 80% IncRNA, with most of these IncRNAs not being DE. This dominance of non-DE IncRNAs in psoriasis-correlated modules may be due to the overall low-abundance of IncRNAs and inability of differential expression methods to detect minute (and statistically insignificant) but biologically significant differences in IncRNA expression, with coding genes having nearly ten times more abundance than IncRNAs on average [22]. As coexpression network analysis is based on pairwise correlations between genes and not on relative differences in expression between biological states, coexpression network analysis may be more robust to inclusion of low-abundance transcripts compared to differential expression analysis. This dominance of IncRNAs in psoriasis-correlated modules suggests the possibility that IncRNAs play a significant role in psoriasis pathogenesis through regulation of coding genes in key pathways. Previous studies of IncRNA indicate they can act by guiding chromatin modifiers and histone modifiers to targeted loci to regulate transcription, function as ligands for proteins, and play

---

**Table 4** Top 10 GO Term and Broad MSigDB Canonical Pathway enrichments for 2 most correlated modules in PPvPT

| Module         | GO Term                                               | pGO     | Broad MSigDB Canonical Pathway                           | pBroad |
|----------------|-------------------------------------------------------|---------|----------------------------------------------------------|---------|
| Sienna3        | regulation of leukocyte mediated cytotoxicity         | 1.40E-05| Genes involved in Lipid digestion, mobilization, and transport | 1.70E-05|
|                | regulation of cell killing                            | 1.90E-05| Antigen processing and presentation                      | 0.0002  |
|                | leukocyte activation                                  | 0.0001  | Genes involved in Neuronal System                        | 0.0004  |
|                | T cell activation                                     | 0.0001  | Genes involved in Lipoprotein metabolism                 | 0.0004  |
|                | monosaccharide metabolic process                      | 0.0001  | Genes involved in Glucose metabolism                     | 0.0004  |
|                | positive regulation of immune response                | 0.0002  | Visual signal transduction: Cones                         | 0.0005  |
|                | cytokine production                                  | 0.0003  | Signaling events mediated by HDAC Class II               | 0.0008  |
|                | cell surface                                          | 0.0005  | ABC transporters                                         | 0.0011  |
|                | MHC protein binding                                   | 0.0005  | Downstream signaling in CD8+ T cells                     | 0.0015  |
|                | microtubule organizing center                         | 0.0006  | Genes involved in Transmission across Chemical Synapses  | 0.0015  |
| Lightyellow    | protein complex disassembly                           | 1.00E-10| Ribosome, cytoplasm                                       | 2.10E-11|
|                | protein targeting to ER                               | 1.10E-10| Ribosome                                                 | 3.50E-11|
|                | establishment of protein localization to endoplasmic reticulum | 1.10E-10| Genes involved in 3’-UTR-mediated translational regulation | 6.90E-11|
|                | viral infectious cycle                                 | 2.20E-10| Genes involved in Translation                           | 3.70E-10|
|                | macromolecular complex disassembly                    | 3.10E-10| Genes involved in Peptide chain elongation                | 7.30E-10|
|                | ribosomal subunit                                     | 4.50E-10| Genes involved in Influenza Viral RNA Transcription and Replication | 1.40E-09|
|                | cytosolic part                                        | 3.50E-09| Genes involved in Nonsense Mediated Decay Enhanced by the Exon Junction Complex | 1.70E-09|
|                | establishment of protein localization to organelle    | 5.70E-09| Genes involved in SRP-dependent cotranslational protein targeting to membrane | 1.90E-09|
|                | cellular component disassembly at cellular level      | 1.20E-08| Genes involved in Influenza Life Cycle                   | 4.30E-09|
|                | cellular component disassembly                        | 1.30E-08| Genes involved in Metabolism of proteins                  | 5.30E-09|

Ahn et al. BMC Genomics (2016) 17:841 Page 6 of 10
crucial roles in cell differentiation that ultimately determine cell fate [23].

**Module enriched for metabolic activity**

The blue module, the most correlated module in PPvNN, was enriched for lipid metabolic pathways as well as biosynthetic pathways. This finding is in line with the results of Gudjonsson et al. [3, 24] that uncovered DE genes also enriched for lipid metabolism along with biosynthetic pathways. Several of the downregulated genes enriching for these pathways in Gudjonsson et al. [24] were also downregulated in our analysis and found in the blue module, including PPARA, ELOVL3, ACSBG1, and HSD3B1. Gudjonsson et al. [3] inferred that this enrichment for lipid and fatty acid metabolic pathways is associated with defects in the epidermal lipid barrier of psoriatic skin. However, there is mounting evidence that perturbations of lipid metabolic pathways may also be associated with T cell fate and function [25], particularly in T<sub>reg</sub> cells [26]. It has very recently been shown that short-chain fatty acids promote differentiation of naïve T cells into T<sub>reg</sub> cells [27, 28] and that dysfunctional T<sub>reg</sub> cells residing in the skin are thought to contribute to the pathogenesis of psoriasis [29]. Therefore, we found it very interesting that genes involved in short-chain fatty acid metabolic pathways including propionate metabolism and butyrate metabolism were enriched in the blue module and that the majority of these genes were significantly downregulated, which could potentially lead to T<sub>reg</sub> dysfunction. As recent studies of immune cell metabolism in other autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus suggest that disease and T cell specific metabolic profiles regulate pathogenic responses [25], our data suggest that future T cell metabolism studies in psoriasis are warranted.

**Module enriched for olfactory receptor activity**

One of our most surprising and intriguing findings was the enrichment of negatively regulated olfactory receptor genes in the PPvNN salmon module (second most correlated module in PPvNN). Since the discovery that olfactory receptors are expressed in non-nasal tissue, olfactory receptor expression has been observed in skin tissue and specifically in keratinocytes, dendritic cells, and melanocytes. Most recently, Busse et al.[30] discovered that OR2AT4, an olfactory receptor gene, is expressed in keratinocytes and that exposure to a synthetic odorant activated a calcium signal transduction pathway that induced wound healing. Jabbari et al. [31] and Li et al. [5] revealed that OR2T10, OR2T11, OR52B6, OR9Q1, OR10V1, OR1L8, OR2A1, OR2A20P, OR2A42, and OR2A9P were down-regulated while OR1J1 and ORMDL2 were up-regulated. While OR2AT4 is not a DEG in our analysis or
in previous studies [5, 31, 32] and is not a member of a module significantly correlated with psoriasis in PPvNN or PPvPT, we nonetheless observed that the salmon module was significantly enriched for olfactory signaling and transduction canonical pathways, a finding that bolsters our previous analysis of this data using a complementary coexpression analysis method [21]. Furthermore, Li et al. [5] had also reported that a module detected via WGCNA that was significantly correlated with psoriasis was significantly enriched for “olfactory receptor activity”.

**Hub genes in blue module**

Within the blue module, we identified 33 hub genes or genes with high GS (GS ≥ 10) and high connectivity between genes (MM ≥ 0.8) (Fig. 2b) of which 32 were DEGs, including 5 lncRNAs (Additional file 5). The gene with the highest GS was HOXA10 while the gene with the highest MM was GGH. HOXA10, is a homeobox gene that encodes a DNA-binding transcription factor that has been implicated in endometriosis [33], oncogenesis [34], and most recently in innate immune response regulation [35]. In a study of B cell differentiation, Yasmeen et al. [36] demonstrated that the knockout of an aldehyde dehydrogenase-1 enzyme involved in retinol metabolism and retinoic acid synthesis and encoded by the ALDH1 family of genes resulted in increased expression of HOXA10 by downregulating the expression of the anti-inflammatory transcription factor peroxisome proliferator-activated receptor PPARG. ALDH1L1, another hub gene in the blue module, is negatively coexpressed with HOXA10 and while PPARG is not a hub gene in the blue module, it is significantly downregulated in PPvNN. Hub gene CD200, is a gene that encodes for a transmembrane glycoprotein and has been shown to attenuate inflammatory response and promote immune tolerance [37, 38] and is downregulated in PPvNN. The gene encoding for fatty acid binding protein, FABPS, is another hub gene was upregulated and highly connected in the PPvNN blue module and has been shown previously to interact with psoriasisin (S100A7) [39] and is highly expressed in psoriatic epidermal tissue [40]. The final hub gene of note was the transmembrane protein encoding gene, TMEM57, which was upregulated and highly connected in PPvNN and while it has not yet been implicated in psoriasis pathogenesis directly, a TMEM57 variant was found to be associated with a biomarker for inflammation in a Sardinian population [41].

**Treatment with adalimumab normalizes perturbed pathways**

We found that for a number of GO term enrichments and Broad MSigDB canonical pathways, dysregulated pathways in psoriasis (either overexpressed or underexpressed in PPvNN) reverted towards the baseline after adalimumab treatment in PPvPT (Additional file 2). For instance, while the GO terms, “viral reproductive process”, “nuclear division”, and “mitosis” are significantly enriched for upregulated genes in PPvNN, these same terms are significantly enriched for downregulated genes in PPvPT. The top canonical pathways in PPvNN, “olfactory transduction”, “genes involved in olfactory signaling pathway”, and “genes involved in cell cycle”, also reversed direction, suggesting that these return towards a pre-psoriatic baseline with biologic treatment. To investigate the possibility that treatment with adalimumab may have caused reversal of pathway direction beyond the baseline in controls, we also examined the enrichment for GO terms and canonical pathways in NN vs PT. We found that for all of the pathways that reverted towards the baseline in PPvPT, none appear to “overshoot” the baseline.

**Evaluation of putative psoriasis autoantigen**

While it has long been thought that an autoantigen may trigger T-cell activation and subsequent development of psoriasis in susceptible individuals, characterization of the responsible autoantigen has been elusive. Very recently, Lande et al. [42] revealed that LL37/CAMP is recognized as an autoantigen by T cells in nearly 50% of psoriasis patients and much more frequently in cases of moderate-to-severe psoriasis. CAMP was marginally downregulated in PPvNN (p = 0.01, q = 0.059) and was coexpressed in the blue module in PPvNN. CAMP was also significantly downregulated in PPvPT (p = 1.5e-3, q = 1.4e-2) but was not coexpressed in any module. Genes that were highly coexpressed with CAMP within the blue module were enriched for metabolic pathways such as fatty acid metabolic process and lipid biosynthesis, pathways that were enriched for in the blue module as a whole.

**Conclusions**

In summary, combining complementary systems biology approaches such as WGCNA with DE analysis has significant advantages over DE analysis alone. For instance, while single gene DE analysis revealed the downregulation of lipid biosynthesis and fatty acid metabolism, network analysis revealed specific short-chain fatty acid metabolic pathways and how these genes may be interacting with each other. We also found that olfactory receptor signaling is significantly enriched for in one of the top associated modules in PPvNN, an interesting observation in light of recent discoveries highlighting the role of olfactory receptors in signal transduction and wound healing in the skin. We discovered that the majority of the top significantly associated modules were composed of lncRNAs, with 90% of the top 10 PPvNN modules consisting of at least 80% lncRNAs and 70% of the top 10 PPvPT modules consisting of at least 70% lncRNAs. This
suggests that lncRNAs likely play a significant role in the regulation of critical pathways in the pathogenesis of psoriasis. Here for the first time we have also described the impact of the TNF-α inhibitor, adalimumab, on these gene networks, with dysregulated pathways reverting back to a pre-psoriatic baseline.

We believe that future studies of populations of isolated individual cell types (i.e. keratinocytes, T cell subsets, dendritic cells, etc.) and single-cell approaches will allow researchers to precisely match each gene network to a particular cell type, shedding further light on which cells are triggering psoriasis and which cells may be conferring resistance to currently available therapies. This matching of gene networks to cell type (and sub cell type) may also aid in functional analyses of lncRNAs, a vast majority of which have no known function. These functional analyses will likely involve the use of siRNA or the more recently developed CRISPRi technologies to perturb genes of interest in each network.

**Acknowledgments**

All participants provided written informed consent for participating in the study which was approved by the UCSF institutional review board. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

All participants provided written informed consent for participating in the study which was approved by the UCSF institutional review board.

**Author details**

1. Department of Dermatology, University of California, San Francisco, 2340 Sutter Street, Box 0808, San Francisco, CA 94143-0808, USA. Current address: Icahn School of Medicine at Mount Sinai, New York, NY, USA.

**Received:** 26 May 2016 Accepted: 22 October 2016

**Published online:** 28 October 2016

**References**

1. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftagut K, Catier J, Fernandez-Vina MA, Menter A. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet. 2001;10:1793–805.

2. Zhou X, Krueger J, GiG, Kao M, JC, Lee E, Du F, Menter A, Wong WHH, Bowcock AMAM. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics. 2003;1:369–78.

3. Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, Voorhees JJ, Abecasis GR, Elder JT. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol. 2010;130:1829–40.

4. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Voorhees JJ, Abecasis GR, Nair RP, Voorhees JJ, Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Voorhees JJ, Abecasis GR, Nair RP, Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol. 2010;130:1213–26.

5. Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Tejasvi T, Johnston A, Ding J, Stuart PE, Xing Y, Kochkodan JJ, Voorhees JJ, Kang HM, Nair RP, Abecasis GR, Elder JT, Transcriptome Analysis of Psoriasis in a Large Case–control Sample: RNA-Seq Provides Insights into Disease Mechanisms. J Invest Dermatol. 2014;134:1828–38.

6. Stuart JM. A Gene-coexpression Network for Global Discovery of Conserved Genetic Modules. Science (80-). 2003;302:249–55.

7. Schäfer J, Strimmer K. An empirical Bayes approach to inferring large-scale gene association networks. Bioinformatics. 2005;21:754–64.

8. Colussi S, Hines J, Bowcock AM, Grahn J, Krueger J, Elder JT. Transcriptome Analysis of Psoriasis in a Large Case-control Sample: RNA-Seq Provides Insights into Disease Mechanisms. J Invest Dermatol. 2014;134:1828–38.

9. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

10. Subramanian A, Tamayo P, Mootha VK, Mukhejee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.

11. Horvath S, Zhang B, Clarkson M, Lu J, Zhu S, Feclano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liu LM, Wu H, Geschwind DH, Fejdo Pot, Kornblum HI, Cloughesy TF, Nelson SF, Michels PS. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A. 2006;103:17402–7.

**Abbreviations**

CRISPRi: Clustered regularly interspaced short palindromic repeats interference; DEG: Differentially expressed gene; FDR: False-discovery rate; GO: Gene ontology; GS: Gene significance; KEGG: Kyoto Encyclopedia of Genes and Genomes; IncRNA: Long intergenic non-coding RNA; InsRNA: Long non-coding RNA; ME: Module eigengene; MM: Module membership; NN: Healthy control patient; PP: Psoriasis patient; PT: Psoriasis patient, post-treatment; qPCR: Quantitative polymerase chain reaction; siRNA: Small-interfering RNA; TNF-α: Tumor necrosis factor alpha; TOM: Topological overlap matrix; WGCNA: Weighted gene coexpression network analysis

**Funding**

This study was supported by NIH grants to WL (R01 AR065174, U01 AI119125). RA was supported by an NIAWIS postdoctoral training grant to the Department of Dermatology at the University of California, San Francisco (T32 AR007175-38). The funding bodies played no role in the collection, analysis, or interpretation of data in this study.

**Availability of data and materials**

The dataset supporting the conclusions of this article is available in the NCBI’s Gene Expression Omnibus (GEO) repository, GSE74697 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74697).

**Authors’ contributions**

WL conceived and designed the experiments. RA, KL, and NC analyzed data. RA and WL wrote the paper. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

All participants provided written informed consent for participating in the study which was approved by the UCSF institutional review board.

**Additional files**

**Additional file 1:** List of differentially expressed genes. The full list of genes that were differentially expressed (FDR ≤ 0.05) in (1) PPvNN and (2) PPvPT. (XLS 709 kb)

**Additional file 2:** List of GO terms enriched for amongst differentially expressed genes. The full list of GO terms that are enriched for amongst the differentially expressed genes in (1) PPvNN and (2) PPvPT. Direction indicates whether genes enriching for a given GO term are overexpressed (up) or underexpressed (down). (XLS 336 kb)

**Additional file 3:** List of GO and Broad MSigDB terms enriched for in the top correlated modules of PPvNN. The full list of GO and Broad MSigDB terms enriched for (p ≤ 0.005) in the blue and salmon modules of PPvNN. (XLS 237 kb)

**Additional file 4:** List of GO and Broad MSigDB terms enriched for in the top correlated modules of PPvPT. The full list of GO and Broad MSigDB terms enriched for (p ≤ 0.005) in the sienna3 and lightyellow modules of PPvPT. (XLS 83 kb)

**Additional file 5:** Hub genes of the blue module. List of the hub genes in the PPvNN blue module (GS ≥ 10, MM ≥ 0.8). (TXT 747 bytes)

**Additional file 6:** Intramodular analysis of most correlated modules. Plots of MM vs GS to explore hub genes for the top 3 most correlated modules in (1) PPvNN and (2) PPvPT. (PDF 730 kb)
